Drug Profile
JT 07 - JYANT Technologies
Alternative Names: JT07Latest Information Update: 28 Sep 2020
Price :
$50
*
At a glance
- Originator JYANT Technologies
- Class Antibodies
- Mechanism of Action CXCR3 receptor antagonists; CXCR7 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Inflammatory bowel diseases; Solid tumours
Most Recent Events
- 28 Sep 2020 No recent reports of development identified for preclinical development in Inflammatory-bowel-diseases in USA
- 28 Sep 2020 No recent reports of development identified for preclinical development in Solid-tumours in USA
- 12 Aug 2016 Preclinical trials in Inflammatory bowel disease in USA (unspecified route)